Florida Cancer Care

Boca Raton Plantation
p. 561.727.3800
f.  561.727.3810
p. 954.582.1850
f.  954.582.1860

Research

In early 2006, Dr. Tan-Chiu founded Florida Cancer Research Institute (FCRI). FCRI's staff and state-of-the-art facility offer FDA approved clinical research trials giving its patients alternatives other than generic therapies usually offered by other general oncologist. We encourage our patients and physicians to join our network and help make vital contributions to the development of new and better therapies for the treatment of cancer.

Disease Protocol Title Status
Metastatic breast 120BC201
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in CombinationWith Exemestane in Women with Hormone Receptor-Positive, Advanced MetastaticBreast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Closed
Metastatic breast 3144A2-3003-WW
A Phase III, Randomized, Open-Laber Study of Neratinib vs. Lapitinib Plus Capecitabine for the Treatment of ErbB-2 Positive Locally Advanced or Metastatic Breast Cancer
Closed
Adjuvant Breast 3144A2-3004-WW
A Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women with Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer
Closed
Metastatic Breast 3144A2-3005-WW
A Phase 3, Randomized, Open-Label, Two-arm study of Neratinib Plus Paclitaxel versus Trastuzumab plus Paclitaxel as first-line treatment for ErbB-2-positive Locally recurrent or metastatic Breast Cancer
Closed
Metastatic breast 3160A6-2206-WW
Phase 2, Randomized, Open-Label Study of Bosutinib Administered in Combination with Exemestane vs. Exemestane Alone as Second Line Therapy in Post-Menopausal Women with Locally Advanced or Metastatic ER+/PgR+/ErbB2-Breast Cancer
Closed
Metastatic breast A4021004
A Two-Arm Randomized Open Label Phase 2 Study of CP-651,871 in Combination with Exemestane Verses Exemestane Alone as First LIne Treatment for Postmenopausal Patients with Hormoe Receptor Positive Advanced Breast Cancer
Closed
Metastatic breast A6181094
A Phase III study of SU011248 in Combination with Paclitaxel Verses Bevacizumab with Paclitaxel in the First-Line Advanced Disease Setting in Patients Having Breast Cancer
Closed
Metastatic breast AVF4349n VIRGO
An Observational Study of Treatment Patterns andd Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer
Closed
Metastatic Breast BAY 43-9006/12444
A Phase III Randomized, Double blind, Placebo-controlled Trial Comparing Capecitabine Plus Sorafenib Versus Capecitabine Plus Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer
Closed
Adjuvant Breast BO20906 BETH
A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy plus Trastuzumab Plus Bevacizumab
Closed
Metastatic Breast C14007
A Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gastro esophageal Malignancies
Closed
Ovarian C14008
Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Closed
Neoadjuvant breast CA163100
A Randomized Phase II Biomarker Neoadjuvant study of Sequential AC followed by Ixabepilone Compared to Sequential AC followed by Paclitaxel in Women with Early Breast Cancer
Closed
Metastatic breast CRAD001Y2301
A randomized double-blind, placebo-controlled study of Everolimus in combination with Exemestane in the treatment of postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer who are refractory to Letrozole or Anastrozole.
Closed
Metastatic breast DOCET_L_00712
A Pilot, Phase II Multicenter Open-Label Prospective Study of Docetaxel and Bevacizumab +/- Trastuvumab in the First-Line Treatment of Patients with Metastatic Breast Cancer
Closed
Metastatic breast E7389-G000-301
A Phase III, Open Label, Randomized Two-Parallel-Arm Multicenter Study of E7389 versus Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes and Refractory to the Most Recent Chemotherapy
Closed
Metastatic breast E7389-G000-305
A Phase III Open Label, Randomized Parallel Two-Arm Multi Center Study of E7389 versus ‘ Treatment of Physician's Choice' in Patients with Locally Recurrent or Metastatic Breast Cancer, Previously Treated with At Least Two and a Maximum of Five Prior Chemotherapy Regimens, Including an Anthracycline and a Taxane.
Closed
Metastatic Breast E7839-A001-206
A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Closed
Metastatic Breast INCB7839-204
A Phase I/II study to assess the safety and therapeutic effect of INCB007839 in combination with trastuzumab and vinorelbine in patients with metastatic HER2+ breast cancer
Closed
Metastatic breast IPI-504-07
A Phase 2 Multicenter Study Evaluating the Efficacy andSafety of IPI-504 in Combination with Trastuzumab inPatients with Pretreated, Locally Advanced or MetastaticHuman Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
Closed
Metastatic breast LPT111110
A Phase II Single-Arm Multicenter Study Evaluating the Combination of Vinorelbine and Lapatinib in Women with ErbB2 Overexperessing (HER2+) Metastatic Breast Cancer
Closed
Neoadjuvant breast ML18530
An Open-Label Study of Capecitabine and Docetaxel as Neoadjuvant Treatment for Patients with Recently Diagnosed Her2-neu Negative Breast Cancer Plus Trastuzumab for Her2-neu Positive Breast Cancer
Closed
Metastatic breast NKV102549
A Phase III, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist, Casopitant (GW679769) in Combination with Odansetron and Dexamethasone for the Prevention of Nausea and Vomiting Induced Moderately Emetogenic Chemotherapy
Closed
Metastatic breast RAD001J2101
A Phase Ib/II Study Investigating the Combination of Everolimus with Trastuzumab and Paclitaxel in Patients with HER2-Overexpressing Metastic Breast Cancer
Closed
Metastatic breast Ribbon-2 AVF3693g
A Phase III, Multicenter, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination with Chemotherapy Regimens in Subjects with Previously Treated Metastatic Breast Cancer
Closed
Cancer Control Study SNX-1012-CLN2-006
A Phase II, Double-masked, Placebo-Controlled Study to Evaluate the Efficacy of SNX-1012 in Reducing the Duration and Severity of Ulcerative Oral Mucositis in Patients Receiving Cytotoxic Chemotherapy for Colorectal, Breast, or Lung Cancer
Closed
Metastatic breast TCD10037
Open label, Uncontrolled, Study of XRP9881 (larotaxel) in combination with weekly Trastuzumab (Herceptin) in Patients with HER2 Positive Metastatic Breast Cancer
Closed
Cancer Control Study TDM4347g
A Phase II Single-Arm Open Label Study of Trastuzumab-MCC DM1 Administered Intravenously to Patients with HER2 Positive Metastatic Breast Cancer
Closed
Metastatic Breast TDM4884G
An Expanded Access, Open-Label Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer
Closed
Adjuvant Breast TITAN BRE 145
A random trial of Ixempra vs Taxol in Adjuvant Therapy of Triple Negative Breast Cancer.
Closed
Shingles Vaccine V212
A Phase I, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine Immunocompromised Adults
Closed